Cargando…
AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer
BACKGROUND: Dermatologic toxicities, especially akne-like skin rash, are the most common side-effects associated with anti-epidermal growth factor receptor (EGFR) therapy. Preemptive treatment with oral tetracyclines is recommended as a standard. Topical prophylactic options have thus far not been c...
Autores principales: | Kripp, Melanie, Prasnikar, Nicole, Vehling-Kaiser, Ursula, Quidde, Julia, Al-Batran, Salah-Eddin, Stein, Alexander, Neben, Kai, Hannig, Carla Verena, Tessen, Hans Werner, Trarbach, Tanja, Hinke, Axel, Hofheinz, Ralf-Dieter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739620/ https://www.ncbi.nlm.nih.gov/pubmed/29285233 http://dx.doi.org/10.18632/oncotarget.21249 |
Ejemplares similares
-
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
por: Giessen, Clemens, et al.
Publicado: (2011) -
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
por: Tintelnot, Joseph, et al.
Publicado: (2023) -
RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
por: Lorenzen, Sylvie, et al.
Publicado: (2020) -
EHMTI-0110. Epidemiology of primary headaches in the population of Baku
por: Aliyev, R, et al.
Publicado: (2014) -
VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Thomaidis, Thomas, et al.
Publicado: (2014)